首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 78 毫秒
1.
目的研究原发性生长激素缺乏症(GHD)治疗24个月后身高年龄(HA)和骨龄的变化.方法17例GHD伴促性腺激素缺乏的男性患者,年龄14.8±2.27岁,HA8.16±1.5岁,给予重组人生长激素(rhGH,健高宁)治疗24个月,第13个月起合用绒毛膜促性腺激素或庚酸睾酮,观察疗效. 结果治疗第1年,生长速率(HV)11.25±1.89cm/年,身高年龄增加(△HA)2.13±0.36岁,骨龄增加(△BA)2.17±0.57岁,△HA/△BA1.06±0.36;第2年,HV13.39±2.52cm/年,△HA 2.18±0.59岁,△BA2.05±0.8岁,△HA/△BA1.13±0.29.患者治疗前、治疗后不同阶段的HA皆与BA呈正相关;两年身高标准差积分(HtSDS)增加2.55.结论单用rhGH和合用性激素治疗均对GHD患者有明显的促线性生长和发育作用,并且后者效果更佳;在促身高增加的同时也促骨龄成熟,而且两者平行.  相似文献   

2.
目的研究重组人生长激素(rhGH)治疗生长激素缺乏症(GHD)对肺功能的影响。方法10例GHD伴促性腺激素缺乏的男性患儿,年龄15.6±3.2岁,身高年龄(HA)8.82±1.81岁,给予rhGH(健高宁)治疗,剂量为0.11U·kg  相似文献   

3.
重组人生长激素治疗生长激素缺乏症86例疗效分析   总被引:5,自引:0,他引:5  
目的研究国产和进口重组人生长激素(rhGH)治疗生长激素缺乏症(GHD)的临床效果.方法应用国产rhGH治疗GHD 67例,身高(118.4±14.4)cm,身高SDS-(4.1±1.6).生长速率(3.0±0.8)cm/年.进口rhGH 19例,身高(129.3±9.0)cm,身高SDS-(5.5±1.6),生长速率(2.8±1.1)cm/年.rhGH,每公斤体重每日0.1IU,疗程6个月.结果 rhGH对这些患儿体格的线性生长有显著促进作用(P<0.001),国产rhGH治疗6个月生长速率(12.6±3.6)cm/年,进口rhGH(12.0±2.2)cm/年,两者差异无显著性应用国产rhGH的完全性GHD和部分性GHD6个月的生长速率分别为(13.4±3.7)cm/年和(10.3±2.2)cm/年,两者差异有显著性(P<0.002).本文86例中,骨龄≤5岁和≥7岁6个月生长速率分别为(14.1±3.3)cm/年和(11.  相似文献   

4.
目的 观察国产重组人生长激素 (rhGH)治疗儿童生长激素缺乏症 (GHD)的临床疗效和安全性。方法 对 2 1例GHD以国产rhGH进行治疗 ,每晚临睡前皮下注射 0 .1U/kg ,共 6个月。结果  2 1例患儿身高平均增加 (6 .5 9± 1.5 9)cm ,年生长速度由治疗前的 (2 .79± 1.13)cm/a增加到 (13.78± 4.43)cm/a(治疗 3个月时 )、(13.0 5± 3.12 )cm/a(治疗 6个月时 )。体重也明显增加 ,但对骨龄无明显促进作用。完全性GHD疗效优于部分性GHD(P <0 .0 1)。治疗期间有 2 3.8%的儿童出现亚临床甲状腺功能减低 ,但未影响患儿体格的线性增长。结论 国产rhGH是治疗GHD的一种安全、有效的促生长药物 ,该药对患儿无明显副作用  相似文献   

5.
目的研究国产重组人生长激素(rhGH)治疗生长激素缺乏症(GHD)的临床效果和安全性。方法GHD67例,年龄11.93±3.18岁,身高118.41±14.36cm,生长速率2.95±0.8cm/a。给予国产rhGH,0.1U·kg  相似文献   

6.
目的 基因重组人生长激素(rhGH)治疗矮小症的有效性已得到广泛验证,开始治疗时的骨龄,治疗的疗程、剂量等都可影响rhGH治疗的疗效,本文主要探讨rhGH治疗生长激素缺乏症(GHD)患儿的疗效,观察开始治疗时的骨龄对rhGH疗效的影响。 方法 选择2012年8月—2017年8月安徽省立医院儿科收治的青春期前GHD患儿共42例,分骨龄小于8岁组(<8岁组)23例,骨龄大于等于8岁组(≥8岁组)19例,均接受rhGH治疗6个月,剂量为0.1 IU/(kg·d)。比较2组治疗前后的身高、生长速率(GV)、身高的标准差分值(HtSDS)等;比较治疗后2组间的△GV、△HtSDS。组内治疗前后比较采用配对t检验;2组间比较采用独立样本t检验;两变量之间相关性采用Pearson相关分析。 结果 6个月后,2组的身高、GV、HtSDS均较治疗前明显增高(均P<0.05);<8岁组的△GV、△HtSDS分别为(6.17±1.44)cm/年、0.50±0.13,≥8岁组的△GV、△HtSDS分别为(5.28±0.69)cm/年、0.23±0.17,2组间比较差异有统计学意义(均P<0.05);2组治疗6个月后的△GV、△HtSDS与开始治疗时的年龄、骨龄呈负相关(均P<0.01)。 结论 rhGH治疗GHD患儿疗效肯定,开始治疗时的骨龄越小,疗效越好。   相似文献   

7.
[目的]小剂量司坦唑醇治疗对生长迟缓患儿骨龄的影响及其与疗效的关系.[方法]对15例生长迟缓的患儿,其中部分性生长激素缺乏症10例,体质性生长发育延迟5例.年龄5~13(10.2±1.1)岁,男孩10例,女孩5例.所有患儿均予每日口服司坦唑醇0.02~0.04mg/kg,治疗时间4~16(8.9±4.5)个月,每隔3~6个月复查骨龄及身高,计算患儿生长速度(GV).[结果]15例患儿治疗前后生长速度由(3.95±0.22)cm/年提高到(7.60±2.15)cm/年,身高z评分(HtSDS)均有不同程度的提高,HtSDS由-2.50±0.58提高到-2.27±0.64(P<0.01),按骨龄的身高z评分由-1.04±0.97提高到-0.77±0.76(P<0.05).ΔHtSDSca0.24±0.26,ΔHtSDSba0.19±0.26,身高年龄增长值与骨龄增长值的比值(ΔHA/ΔBA)为1.23±0.47,其中2例ΔHA/ΔBA值小于1.ΔHtSDSca/ΔBA(岁)为0.27±0.24/岁,ΔHtSDSba/ΔBA(岁)为0.30±0.38/岁,其中2例比值为负数.[结论]小剂量司坦唑醇能改善未发育的部分性生长激素缺乏症与体质性生长发育延迟患儿的生长能力,同时骨龄成熟速度亦增加,因此,治疗过程必需密切观察骨龄变化.  相似文献   

8.
目的研究重组人生长激素(rhGH)治疗生长激素缺乏症(GHD)对肺功能的影响。方法 10例GHD伴促性腺激素缺乏的男性患儿,年龄15.6±3.2岁,身高年龄(HA)8.82±1.81岁,给予rhGH(健高宁)治疗,剂量为0.11U·kg-1·d-1,疗程12个月,观察治疗前,治疗后6个月,12个月肺活量(VC)和最大通气量(MVV)变化,并和预计数比较。结果 10例GHD患儿经12个月的rhGH治疗身高增长明显。HA增加2.1岁,年生长速率(HV)比治疗前提高4倍(P<0.001)。VC,MVV治疗后12个月均比治疗前明显增加,两者差异皆具显著性(P<0.05)。但患儿治疗前后的VC,MVV占预计数百分比差异无显著性(P>0.05)。结论 rhGH对GHD患者有明显的促线性生长和发育作用,随体表面积的增加肺功能有相应的改善。  相似文献   

9.
目的:观察重组人生长激素(rhGH)治疗小于胎龄儿(SGA)持续矮小的疗效和安全性?方法:17例出生时为SGA且目前诊为矮小的患儿,随机分为2组,每晚睡前1 h皮下注射rhGH,低剂量组8例,0.1 U/(kg·d),高剂量组9例,0.2 U/(kg·d),观察12个月?结果:17例患儿身高由治疗前(96.34 ± 8.94)cm增至治疗后的(107.32 ± 9.58)cm,骨龄(BA)由治疗前的(2.39 ± 1.28)岁增至(3.64 ± 1.76 )岁,年龄对应身高标准差积分(HtSDSCA)治疗前-3.04 ± 0.79增至治疗后-1.89 ± 0.79,生长速率(GV)由治疗前(4.59 ± 0.87)cm/年增至治疗后(11.24 ± 1.91)cm/年,预测身高(PAH)由治疗前(147.24 ± 5.70)cm,增至治疗后(153.53 ± 6.17)cm?两组患儿治疗前后的变化差异均有统计学意义(P < 0.05)?不同剂量组均有促生长作用,无统计学差异?结论:rhGH对SGA持续矮小患儿有促生长作用,使其达到追赶生长,且不良反应少?  相似文献   

10.
目的研究国产重组人生长激素(rhGH)治疗生长激素缺乏症(GHD)的临床效果和安全性.方法GHD67例,年龄11.93±3.18岁,身高118.41±14.36cm,生长速率2.95±0.8cm/a.给予国产rhGH,0.1U·kg-1·d-1,疗程6月.结果rhGH对患儿体格的线性生长有显著促进作用(P<0.001),完全性GHD和部分性GHD6个月的生长速率分别为13.36±3.73cm/a和10.33±2.21cm/a,两者差别有高度显著性(P<0.01).结论国产rhGH是一种治疗GHD的有效药物,近期效果和进口的rhGH相似,并且完全性GHD的疗效比部分性GHD好.  相似文献   

11.
Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P < 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (>0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P <0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P < 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.  相似文献   

12.
Objective: To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods: SD rats served as both donors and recipients. 4℃ sodium lactate Ringer's was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava (IVC) inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results: Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion: This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.  相似文献   

13.
Objective To observe blood pressure change with age in salt-sensitive teenagers whose salt sensitivity were determined by repeated testing.Methods Salt sensitivity was determined through intravenous infusion of normal saline combined with volume-depletion by oral diuretic furosemide in 55 teenagers. After five years, salt sensitivity was re-examined and subject blood pressure was followed up. Blood pressure changes in salt-sensitive teenagers were compared to that of non-salt sensitive teenagers over five years.Results After 5 years, the repetition rate of salt sensitivity determined by intravenous saline loading is 92.7%. In teenagers with salt sensitivity on the baseline, both the systolic blood pressure increments and increment rates were much higher than non-salt sensitive teenagers (12.7±12.1 mmHg vs. 2.8±5.2 mmHg, P< 0.01; 12.2%± 12.0% vs. 2.5% ±4.4%, P< 0.001,respectively). There was a similar trend for diastolic blood pressure (8.4 ± 6.4 mmHg vs. 3.7 ± 6.4 mmHg, P = 0.052; 13.2% ±10.6 % vs. 6.8%± 10.1%, P = 0.053, respectively).Conclusions Salt sensitivity determined by intravenous saline loading showed good reproducibility. Blood pressure increments with age were much higher in salt-sensitive teenagers than non-salt sensitive teenagers, especially in terms of systolic blood pressure.  相似文献   

14.
Shock wave lithotripsy (SWL) is a treatment of choice for upper urinary stones. However, this procedure is inappropriate for obese patients because the focus is often unable to reach the target owing to the limited focal distance in shock wave source. Although treating such patients in a blast path may increase the application length of shock wave source, it's difficult to find this path on the lithotripter monitor. For this reason, we invented an adjustable calibration marker in order to set an effective focus in the shock wave hath.  相似文献   

15.
Excess production of reactive oxygen species(ROS)of mitochondrion mediated by hyperglycemia is the common pathogenesis of angiopathic complications of diabetes.TCM holds that the damp from the dysfunction of spleen.kidney and liver is the causative factor of complications of diabetes.This is similar to the mechanism of Ros resulting in angiopathic complications of diabetes.When the angiopathic complications of type II diabetes mellitus(T2DM)are difierentiated as caused by turbid damp in TCM can be explained as ROS.Since the obstruction of pathogenic damp in channels and collaterals is said to be the main pathogenesis,the treating principle should be dissolving the damp to remove the obstruction.  相似文献   

16.
INTRODUCTION Obesity is a complex emergent problem, which can be possibly solved not only by the diet but also by the life style and promotion of a constant physical exercise. 1, 2 No doubt careful attentions must be given to the nutritional condition of obese people, the dietary habits, the somatic build (i.e. distribution of fat mass) and the organic functions linked to formation of the fat mass. All the parameters should be constantly monitored before, during and after a diet treatment. 3, 4, 5  相似文献   

17.
People with dysglycemia are at high risk for atherosclerotic diseases. This study aims at investigating the atherosclerotic vascular damage in dysglycemia and its metabolic origin in Tibetan population.  相似文献   

18.
FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…  相似文献   

19.
目的:评价使用安心颗粒对急诊经皮冠状动脉介入术(PPCI)术后生活质量的影响.方法:将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组(术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次)和对照组(仅接受基础药物治疗).所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表(MIDAS)、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果:入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异(P>0.05);出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低(P<0.05);组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低(P<0.05).两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血(P>0.05).两组发生轻度血小板减少症的患者数比较无差异(P>0.05).结论:PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.  相似文献   

20.
Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P<0.01);the MAP decreased(P<0.01)and the HR increased drastically(P<0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号